MedPath

Comparison of Laser Treatment With Clobetasol Therapy in Patients With Lichen Sclerosus

Not Applicable
Recruiting
Conditions
Lichen Sclerosus
Interventions
Drug: Treatment with Clobetasol
Device: Treatment with Monalisa Glide Laser
Registration Number
NCT06135402
Lead Sponsor
Kantonsspital Winterthur KSW
Brief Summary

With this trial the investigators look for the effect of Laser maintenance therapy in patients with vulvar lichen sclerosus compared to the maintenance standard treatment clobetasol propionate.

Detailed Description

Vulvar Lichen sclerosus (VLS) is a chronic inflammatory cutaneous disorder, which can lead to scarring, impaired sexual function and malignancy. Gold standard treatment is topical corticosteroids (TCS) initially daily for 12 weeks. To avoid new flourishing of the disease a life-long maintenance treatment 2x/week is later recommended. Fractional CO2-Laser has shown a positive effect on vulvovaginal skin quality with improvement of urogenital atrophy and also lichen sclerosus. This randomised trial compares efficacy of laser treatment to TCS maintenance as well as the duration of the laser effect.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
120
Inclusion Criteria
  • Pre- or postmenopausal
  • 12 weeks of continuous topical clobetasol treatment completed.
  • Written informed consent
  • German speaking (Study information and IC available only in German)
Exclusion Criteria
  • Contraindication and limitations for the use of Mona Lisa Glide-Laser as described in the instructions for use
  • Contraindication for the use of topic clobetasol
  • History of vulva laser
  • Immune-suppression
  • Pregnancy or planned pregnancy, breast feeding.
  • Clinically significant concomitant diseases states as severe renal failure, hepatic dysfunction, severe cardiovascular disease, cancer.
  • History of vulvar or pelvic radiation therapy
  • Uncertain vulvar findings, which require a biopsy.
  • Acute vulvitis, especially recurrent genital herpes
  • History of vaginal mesh implantation within 6 months preceding this study
  • Known or suspected non-compliance, drug or alcohol abuse
  • Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, dementia, etc. of the subject
  • Participation in another investigation with an investigational drug or another MD within the 30 days preceding and during the present investigation
  • Previous enrolment into the current investigation
  • Enrolment of the PI, his/her family members, employees and other dependent persons

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Clobetasol groupTreatment with ClobetasolMaintenance treatment with vulvar TCS (clobetasol) application 2x/week. Instruction given at trial start and monthly check up for treatment control Daily local skin care with a drug free product of patients' choice.
Laser groupTreatment with Monalisa Glide Laser3 monthly fractional laser treatment according to the user manual (correct applicator, vulvar and vaginal preset). In between daily local skin care with a drug free product of patients' choice.
Primary Outcome Measures
NameTimeMethod
Lichen Score3 months

The difference between the initial Lichen score and the score at 3 month after treatment start = 1 month after EOT

Secondary Outcome Measures
NameTimeMethod
Vulva assessment Scale15 months

Vulva assessment scale at 1, 4, 8 and 12 months after EOT, Scale from 0 (no symptoms) to 12 (symptoms)

Lichen Score Follow up15 months

Lichen score at 4, 8 and 12 months after EOT, Scale from 0 (no symptoms) to 12 (symptoms)

German Pelvic floor questionnaire15 months

Shortened Pelvic floor questionnaire at 1, 4, 8, 12 months after EOT

Trial Locations

Locations (1)

Kantonsspital Winterthur

🇨🇭

Winterthur, Zürich, Switzerland

© Copyright 2025. All Rights Reserved by MedPath